Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Price Sensitive Information

28th Apr 2011 12:48

RNS Number : 6575F
Beximco Pharmaceuticals Ltd
28 April 2011
 



BEXIMCO PHARMACEUTICALS LTD.

 

28th April 2011

 

PRICE SENSITIVE INFORMATION

 

 

Beximco Pharmaceuticals Ltd. ("BPL" or "Company": AIM Symbol: BXP) today announces information for the shareholders of the Company that the Board of Directors at their meeting held on 28th April 2011 has decided the following:

 

 

1.

To recommend the approval of the Financial Statements for the year ended 31 December 2010

:

The results are expected to be announced week commencing 9th May 2011

2.

Date & Time of 35th AGM of the company for the year 2010

:

 2nd July, 2011 at 12.30 PM

3.

Venue of AGM

:

Beximco Industrial Park, Sarabo, Kashimpur, Gazipur, Bangladesh

4.

Proposed Dividend for the year ended 31 December 2010

:

20% Stock Dividend (i.e. 20 shares for every 100 shares held)

5.

Record date

:

11th May , 2011

6.

Net Asset Value as at 31 December 2010

:

Taka 15,974,086,451

7.

Net Asset Value per Share as at 31 December, 2010

:

Taka 78.53

8.

Earnings per share ( EPS) for the year ended 31 December 2010

:

Taka 5.17

9.

Net Operating Cash Flow per share for the year ended 31 December 2010

:

Taka 6.65

 

 

For further information please visit www.beximco-pharma.com or enquire to:

 

Beximco Pharma

Nazmul Hassan, MP

Managing Director

Tel: +880 2 861 9151, ext.2080

 

Md. Asad Ullah, FCS, Company Secretary

Tel: +880 2 8618220-1, Ext 1140

 

Libertas

Jakob Kinde / Thilo Hoffmann

Tel: +44 (0)20 7569 9650

 

Financial Dynamics

Jonathan Birt / Susan Quigley

Tel: +44 (0)20 7269 7169

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

 

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMFVLFLFZFZBBF

Related Shares:

Beximco Pharma
FTSE 100 Latest
Value8,474.74
Change-133.74